Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Autores: Silvio E Inzucchi, R.M. Bergenstal, John Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne Peters, Apostolos Tsapas, Richard Wender, David R Matthews
- Localización: Diabetes care, ISSN-e 0149-5992, Vol. 35, Nº. 6, 2012, págs. 1364-1379
- Idioma: inglés
- Enlaces
- Dialnet Métricas: 43 Citas
-
Resumen
R.M. Bergenstal: membership of scientific advisory boards and consultation for or clinical research support with Abbott Diabetes Care, Amylin, Bayer, Becton Dickinson, Boehringer Ingelheim, Calibra, DexCom, Eli Lilly, Halozyme, Helmsley Trust, Hygieia, Johnson & Johnson, Medtronic, NIH, Novo Nordisk, Roche, Sanofi, and Takeda (all under contracts with his employer). Inherited stock in Merck (held by family) J.B. Buse: research and consulting with Amylin Pharmaceuticals, Inc.; AstraZeneca; Biodel Inc.; Boehringer Ingelheim; BristolMyers Squibb Company; Diartis Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Halozyme Therapeutics; Johnson & Johnson; Medtronic MiniMed; Merck & Co., Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and TransPharma Medical Ltd (all under contracts with his employer) M. Diamant: member of advisory boards of Abbott Diabetes Care, Eli Lilly, Merck Sharp &r Dohme (MSD), Novo Nordisk, Poxel Pharma.
